The previous five chains I mapped from the Hormuz closure traced industrial inputs — crude oil, helium, sulfuric acid, tungsten, urea. Each was devastating in its own way. This one is different. This one reaches into your medicine cabinet.
Three separate supply chains feed the world's pharmacies, and all three run through the same 33-mile strait. They are breaking simultaneously. Not in the future — right now, on Day 33 of the closure.
Three Chains, One Chokepoint
Every generic pill, every IV bag, every syringe in every hospital drawer traces back to petroleum. Not metaphorically. Literally. An estimated 99% of pharmaceutical feedstocks and reagents are petrochemical-derived. Paracetamol comes from phenol, which comes from the cumene process, which starts with benzene and propylene — both from oil. The plastic in an IV bag is polyethylene — from ethylene, from naphtha, from crude. The heat that runs the reactor making your blood pressure medication comes from burning propane — from LPG, from the Gulf.
Here are the three chains, and how each is breaking:
Gulf crude oil → Indian refineries → petrochemicals → API synthesis → generic drugs → your pharmacy
The US gets 47% of its generic prescriptions from India. India gets 40% of its crude oil through Hormuz. That crude feeds refineries that produce the petrochemical precursors — benzene, toluene, propylene, phenol — that Indian API manufacturers convert into active pharmaceutical ingredients. India also imports 68% of its APIs from China, where petrochemical feedstocks face their own constraints. The chain is long, and every link is under stress.
Gulf naphtha → ethylene crackers → polyethylene/PVC → IV bags, syringes, gloves, vial stoppers
Naphtha — the light petroleum fraction that feeds Asia's ethylene crackers — has hit $1,000/mt. South Korea, which imports 77% of its naphtha from the Middle East and holds roughly two weeks of stockpiles, banned naphtha exports five months ago. Korea Vaccine has raised syringe prices 15-20%. Hospital hoarding of syringes, gloves, and tubes is spreading across South Korean facilities. Even when APIs are available, the bottles, bags, and syringes to deliver them may not be.
Gulf LPG → Indian propane/butane → pharma reactor heat + steam generation → drug manufacturing
This is the chain most people don't know about. On March 8, India issued the LPG Control Order — diverting ALL propane and butane from refineries to domestic cooking gas. The logic was survival: 300 million Indian households need cooking fuel. The consequence: ~200 pharmaceutical plants across Gujarat, Maharashtra, Telangana, and Andhra Pradesh are losing the process fuel that heats their reactors. Reliance Jamnagar has already cut off isopropyl alcohol supply. India's government is simultaneously breaking one pharma input (propane) while trying to subsidize another (petrochemical import duty waiver on April 2). Contradiction as policy.
The Buffer Clock
Every country holds medicine buffers. Hospitals stock weeks of supplies. Distributors keep warehouses full. These buffers are not infinite. They are draining. Here is where the major economies stand on Day 33:
| COUNTRY | BUFFER HELD | DAYS ELAPSED | STATUS |
|---|---|---|---|
| United Kingdom | 6-8 weeks (NHS) | 33 of ~42-56 | CRITICAL — 86% of pharmacies can't supply aspirin. Aspirin +2,067%. |
| United States | 25-30 days (distributors) | 33 of ~25-30 | BUFFER EXCEEDED — 56 drugs in shortage (FDA). Experts warn more by mid-April. |
| India | Varies (manufacturing) | 33 | PRODUCING LESS — ~200 plants losing fuel. API prices: paracetamol +80%, cipro +30%. |
| South Korea | ~2 weeks naphtha | 33 of ~14 | HOARDING — Hospitals stockpiling syringes, gloves, tubes. Naphtha exports banned. |
| Japan | Strategic reserves | 33 | STRESSED — PM task force active. Petrochemical cuts announced. No shortages yet. |
The US distributor buffer — the 25-30 days that Cardinal Health, McKesson, and Cencora keep in their warehouses — has now been fully consumed. This does not mean every drug vanishes tomorrow. It means new supply is no longer refilling the system at normal rates. The pipeline is thinning. Which drugs disappear first depends on which APIs were most Gulf-dependent and which had the thinnest margins to begin with.
The UK Is the Canary
The United Kingdom is showing us what happens when the buffers crack.
Aspirin 75mg dispersible: 18p → £3.90. A 2,067% increase. The NHS reimburses £2.18. Pharmacies lose £1.72 per pack they dispense.
— National Pharmacy Association survey, March 2026
86% of UK pharmacies cannot supply aspirin. But aspirin is just the most visible fracture. Co-codamol shortages are projected through June 2026 (exports banned since January 28). Statins are "vanishing from pharmacies." Menopause drugs, ADHD medications, epilepsy drugs — all in shortage. Two-thirds of UK pharmacies made a loss in 2025. 72% of pharmacy owners have raided personal savings to keep their doors open.
The UK is uniquely exposed: 85% of NHS drugs are generics. India supplies 60% of the world's generics. One in five NHS medicines is transported by air — and Gulf air cargo capacity is down 79% with Dubai, Abu Dhabi, and Doha airports closed or restricted. Air cargo rates from India have climbed 200-350%.
India's Impossible Trade-Off
India is the world's pharmacy. It produces 60% of global generics and 20% of global generic APIs. It is also the country most visibly tearing itself apart trying to manage the Hormuz closure.
The government's dilemma is stark:
MARCH 8: LPG CONTROL ORDER
All refinery propane/butane diverted to cooking gas. 300M households need fuel. LPG production +28% in 5 days. ~200 pharma plants lose process fuel.
APRIL 2: DUTY WAIVER
Zero customs duty on 40 petrochemical products (PE, PP, PVC, epoxy, polycarbonate) through June 30. Tries to cheapen imported plastics. Doesn't fix the fuel these plants can't get.
The result is a policy contradiction: the government is breaking one pharmaceutical input while subsidizing another. Indian API prices are surging — paracetamol up 80% (Rs 250 to Rs 450/kg), ciprofloxacin up 30%, glycerine up 64%, solvents rising 20-30% per week. Industry sources allege intermediary hoarding is creating artificial scarcity on top of genuine shortages. The government is considering invoking the Essential Commodities Act to prevent API black-marketing.
India's pharma exports — worth $2 billion at risk — saw estimated losses of $300-600 million in March alone. The Himachal Pradesh pharma cluster at Baddi/Nalagarh, one of India's largest, is facing a raw material shock across the board.
The Cold-Chain Cliff
Not all drugs are equal in a crisis. The most vulnerable are cold-chain medicines — vaccines, insulin, biologics, and cancer therapies that require continuous refrigeration and rapid transit. These drugs have short shelf lives and cannot be rerouted around the Cape of Good Hope with two extra weeks of transit. The Gulf air cargo hubs they depended on — Dubai, Abu Dhabi, Doha — are closed or restricted.
Cold-chain oncology drugs carry roughly three months of stock. We are at Day 33. The margin is not wide.
Who Is Exposed
| COMPANY | CHAIN | EXPOSURE |
|---|---|---|
| Teva (TEVA) | API | World's largest generic drug maker. Heavy India API sourcing. First-order exposure to Indian production cuts. |
| Cardinal Health (CAH) | Distribution | 25-30 day buffer. Day 33. Pipeline thinning on generics. Margin risk if costs passed through. |
| McKesson (MCK) | Distribution | Same buffer dynamics as CAH. Largest US pharma distributor by revenue. |
| Cencora (COR) | Distribution | Completes the Big Three. Combined, these three distribute >90% of US pharmaceuticals. |
| Baxter (BAX) | Plastics | IV bags. Polyethylene-dependent. Naphtha at $1,000/mt. Already faced IV bag shortage after Hurricane Helene. |
| Becton Dickinson (BDX) | Plastics | Syringes. Polypropylene-dependent. South Korean hospital hoarding signals demand surge. |
| Sun Pharma / Dr. Reddy's / Cipla | API + Fuel | India's top generic exporters. Triple-hit: API cost surge, propane diversion, petrochemical shortage. |
| Terumo (Japan) | Plastics | Medical devices. Japanese petrochemical production cuts affecting input supply. |
The Convergence
What makes this chain different from every other Hormuz disruption I've mapped is that three independent failure modes are converging on the same shelf. A pharmacy doesn't just need the drug — it needs the drug (API chain), in a container (plastics chain), manufactured with heat (fuel chain). Lose any one and the shelf goes empty. All three are failing.
And unlike helium or sulfuric acid or tungsten, this chain touches everyone. Not semiconductor fabs. Not EV battery plants. Not defense contractors. Everyone. The person who needs aspirin for their heart. The cancer patient waiting for an IV drip. The diabetic who needs insulin kept cold across a supply chain that no longer has functioning air cargo hubs.
THE TIMELINE
US distributor buffers (25-30 days) are past depletion. UK already experiencing shortages in aspirin, statins, co-codamol. India producing less — not nothing, but less — and at higher cost. South Korea hoarding. Japan bracing. The consumer-visible shortages in the US and Europe are likely to become widespread by mid-to-late April. Cold-chain biologics — the drugs with the smallest margin of safety — will be first.
Today the UN Security Council votes on Bahrain's resolution to authorize force to reopen the Strait of Hormuz. Russia and China are expected to veto it. If they do, there is no international legal or military pathway to reopen the strait. The mine-clearing alone, once hostilities end, will take months. The pharmaceutical supply chain does not have months. It has weeks. Some parts of it have days.
This is chain #7 from the Hormuz Cascade. The one that reaches into the medicine cabinet. Previous chains: helium, sulfuric acid, tungsten, urea/fertilizer.